{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:32:31Z","timestamp":1790332351499,"version":"4.1.0"},"reference-count":17,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The eradication of hepatitis C virus (HCV) with interferon-free direct-acting antivirals (DAAs) has transformed the management of chronic HCV infection. Chronic HCV infection is associated with an increased risk of type 2 diabetes mellitus (T2DM) and poor glycemic control. However, the magnitude and consistency of improvement in glycated hemoglobin (HbA1c) after DAA-induced sustained virologic response (SVR) in patients with established T2DM remain unclear. We conducted a systematic review and meta-analysis of six cohort studies comprising 2805 patients. Overall, DAA therapy was associated with a significant reduction in HbA1c after SVR, with a pooled random-effect mean difference of \u22120.45% (95% CI \u22120.74% to \u22120.16%; I2 = 97.8%). This effect is highly heterogeneous but suggests that HCV may be a modifiable contributor to chronic hyperglycemia. These findings highlight the need for close glucose monitoring and individualized adjustment of antidiabetic therapy after SVR to optimize metabolic outcomes.<\/jats:p>","DOI":"10.3390\/v18020239","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:09:32Z","timestamp":1770998972000},"page":"239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Direct-Acting Antiviral Therapy on Glycemic Control in Patients with Chronic Hepatitis C and Type 2 Diabetes: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1514-9575","authenticated-orcid":false,"given":"Jing-Hong","family":"Hu","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Yunlin Chang Gung Memorial Hospital, Yunlin 638, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4902-4401","authenticated-orcid":false,"given":"Ming-Ling","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, and College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9348-8153","authenticated-orcid":false,"given":"Ming-Shyan","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Jung","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yunlin Chang Gung Memorial Hospital, Yunlin 638, Taiwan"},{"name":"Department of Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi 613, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-5204","authenticated-orcid":false,"given":"Yung-Yu","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, December 10). Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","first-page":"3","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1478-3231.2008.01950.x","article-title":"Hepatitis C virus, steatosis and lipid abnormalities: Clinical and pathogenic data","volume":"29","author":"Negro","year":"2009","journal-title":"Liver Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hammerstad, S.S., Grock, S.F., Lee, H.J., Hasham, A., Sundaram, N., and Tomer, Y. (2015). Diabetes and Hepatitis C: A Two-Way Association. Front. Endocrinol., 6.","DOI":"10.3389\/fendo.2015.00134"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review","volume":"166","author":"Nelson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_9","first-page":"775","article-title":"Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control","volume":"26","author":"Andres","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4093\/dmj.2017.41.4.316","article-title":"Factors Associated with Improved Glycemic Control by Direct-Acting Antiviral Agent Treatment in Egyptian Type 2 Diabetes Mellitus Patients with Chronic Hepatitis C Genotype 4","volume":"41","author":"Dawood","year":"2017","journal-title":"Diabetes Metab. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6438753","DOI":"10.1155\/2020\/6438753","article-title":"Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus","volume":"2020","author":"Mada","year":"2020","journal-title":"Int. J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jgh3.12474","article-title":"Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study","volume":"5","author":"Takahashi","year":"2020","journal-title":"JGH Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2025, December 10). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases","volume":"61","author":"Negro","year":"2014","journal-title":"J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:13:03Z","timestamp":1770999183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020239"],"URL":"https:\/\/doi.org\/10.3390\/v18020239","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}